Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation

Hongliang Tian, Chen Ye, Bo Yang, Jiaqu Cui, Zhijun Zheng, Chunyan Wu, Shailan Zhou, Xiaoqiong Lv, Nan Qin, Huanlong Qin, Ning Li, Qiyi ChenFrontiers in Medicine 2022 · DOI

TL;DR

This study reveals significant differences in the gut microbiome composition and function between individuals with Slow Transit Constipation (STC) and healthy controls. These microbial and metabolic alterations show promise as diagnostic and predictive biomarkers for STC, potentially paving the way for novel microbiome-based therapies.

What Problem Does This Paper Address?

Chronic constipation, particularly Slow Transit Constipation (STC), is a common and often debilitating gastrointestinal disorder. While its pathogenesis is complex and involves multiple factors like the enteric nervous system and smooth muscle function, the precise role of the gut microbiome remains incompletely understood. Previous research has hinted at a connection between gut microbiota disturbances and constipation, but a comprehensive metagenomic analysis specifically for STC, exploring both taxonomic and functional profiles, was lacking. This paper aims to fill that gap by investigating the gut metagenome of STC patients to identify potential diagnostic and predictive biomarkers.

Methods

The researchers employed quantitative metagenomics, a powerful technique that analyzes the entire genetic material of a microbial community. This involved:

  • DNA Extraction and Sequencing: Fecal samples were collected and DNA was extracted using a commercial kit. Libraries were constructed and sequenced using the Illumina Hiseq platform, generating a substantial amount of sequencing data.
  • Bioinformatic Analysis: Raw sequencing reads underwent rigorous quality control, trimming, and removal of human DNA.
  • De Novo Assembly: Short reads were assembled into longer contiguous sequences (contigs) using SOAPdenovo.
  • Gene Prediction: Genes were predicted from the assembled contigs using Meta-Gene Marker.
  • Taxonomic Profiling: Microbial composition at different taxonomic levels (phylum, genus, species) was determined using the MetaPhlAn2 program.
  • Functional Profiling: Gene abundances were calculated, and these genes were annotated against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to identify enriched pathways.
  • Statistical Analysis: Various statistical tests, including t-tests, chi-squared tests, and Wilcoxon signed-rank tests, were used to compare differences between STC patients and healthy controls.
  • Biomarker Model Construction: Receiver Operating Characteristic (ROC) curve analysis was used to identify the most discriminatory species and KEGG Orthology (KO) markers for constructing classification models.

Datasets

The study utilized two cohorts of Chinese individuals:

  • Discovery Cohort: 50 patients with STC and 40 healthy controls.
  • Validation Cohort: 16 patients with STC and 12 healthy controls.

This approach allowed for the initial identification of potential biomarkers in the discovery set and subsequent validation in an independent set, increasing the reliability of the findings.

Key Insights and Ideas

  • Distinct Microbial Signatures: The gut microbiome of STC patients is significantly different from that of healthy individuals across multiple taxonomic levels (phylum, genus, species). This suggests a direct link between gut microbial dysbiosis and the condition.
  • Enrichment of Specific Genera: Patients with STC showed markedly higher levels of Alistipes and Eubacterium, while healthy individuals had a higher abundance of the Roseburia genus. This points to specific bacterial players involved in STC.
  • Functional Pathway Alterations: Beyond just the presence of microbes, the functional pathways encoded by the gut metagenome were also significantly different. Notably, pathways related to fatty acid biosynthesis, butanoate metabolism, and methane metabolism were differentially enriched in STC patients.
  • Biomarker Potential: The study successfully constructed classification models using microbial species and KEGG Orthology markers that could distinguish between STC patients and healthy controls with high accuracy. This highlights the potential of these markers for diagnostic and predictive purposes.
  • Methane Metabolism Link: The enrichment of methane metabolism pathways in STC patients is particularly intriguing, as methane production is known to affect intestinal motility. This finding suggests methane quantification could be a diagnostic tool for STC.

Key Results

  • Taxonomic Differences: Significant differences were observed in the abundance of various phyla, genera, and species between STC patients and healthy controls. For instance, Alistipes and Eubacterium were enriched in STC, while Roseburia was lower.
  • Functional Differences: KEGG pathway analysis revealed significant differences in pathways like fatty acid biosynthesis, butanoate metabolism, and methane metabolism.
  • Classification Model Performance:
    • A model based on 15 species markers achieved an Area Under the Curve (AUC) of 88.65% in the discovery set and 78.65% in the validation set.
  • A model based on 10 KEGG Orthology (KO) markers achieved an AUC of 95.15% in the discovery set and 79.69% in the validation set.

Limitations and Future Work

The authors acknowledge several limitations:

  • Fecal vs. Mucosal Microbiome: The study analyzed fecal samples, which may not fully represent the mucosal-adherent bacteria, a potentially more relevant community for gut function.
  • Dietary Influence: A thorough dietary survey was not conducted, and diet is a significant factor influencing the gut microbiome.
  • Sample Size for Validation: While a validation cohort was used, it was smaller than the discovery cohort.
  • Cause vs. Consequence: It remains to be definitively determined whether the observed microbial alterations are a cause or a consequence of STC.

Future work should focus on:

  • Larger Clinical Trials: Testing the diagnostic and predictive biomarkers in larger, independent cohorts.
  • Mechanistic Studies: Investigating the precise mechanisms by which the altered microbiome and its metabolites contribute to STC.
  • Therapeutic Interventions: Exploring microbiome-based therapies, such as probiotics or prebiotics, to restore gut balance and improve STC symptoms.
  • Mucosal Microbiome Analysis: Investigating the role of mucosal-adherent bacteria in STC.
  • Dietary Impact: Incorporating detailed dietary assessments in future studies.

Summary updated

Abstract

Slow transit constipation (STC) is one of the most frequent gastrointestinal diagnoses. In this study, we conducted a quantitative metagenomics study in 118 Chinese individuals. These participants were divided into the discovery cohort of 50 patients with STC and 40 healthy controls as well as a validation cohort of 16 patients and 12 healthy controls. We found that the intestinal microbiome of patients with STC was significantly different from that of healthy individuals at the phylum, genus, and species level. Patients with STC had markedly higher levels of Alistipes and Eubacterium and lower abundance of multiple species belonging to the <i>Roseburia</i> genus. Patients with STC gene expression levels and the Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology pathway (such as fatty acid biosynthesis, butanoate metabolism, and methane metabolism pathways) enrichment were also substantially different from those of healthy controls. These microbiome and metabolite differences may be valuable biomarkers for STC. Our findings suggest that alteration of the microbiome may lead to constipation by changing the levels of microbial-derived metabolites in the gut. Above findings may help us in the development of microbial drugs.
BibTeX
@inproceedings{tian2022gut,
  author = {Hongliang Tian and Chen Ye and Bo Yang and Jiaqu Cui and Zhijun Zheng and Chunyan Wu and Shailan Zhou and Xiaoqiong Lv and Nan Qin and Huanlong Qin and Ning Li and Qiyi Chen},
  title = {{Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.777961},
}
Figure